[HTML][HTML] Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

RH Advani, JJ Buggy, JP Sharman… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
RH Advani, JJ Buggy, JP Sharman, SM Smith, TE Boyd, B Grant, KS Kolibaba, RR Furman…
Journal of Clinical Oncology, 2013ncbi.nlm.nih.gov
Purpose Survival and progression of mature B-cell malignancies depend on signals from the
B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this
pathway. We evaluated ibrutinib (PCI-32765), a small-molecule irreversible inhibitor of BTK,
in patients with B-cell malignancies.
Abstract
Purpose
Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway. We evaluated ibrutinib (PCI-32765), a small-molecule irreversible inhibitor of BTK, in patients with B-cell malignancies.
ncbi.nlm.nih.gov